Aerosol therapy for the treatment of osteosarcoma lung metastases: Targeting the fas/fasl pathway and rationale for the use of gemcitabine

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 4, 2010, Pages 189-196

  Gordon, Nancy ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

aerosol; Fas ligand; Fas APO1; gemcitabine; osteosarcoma

Indexed keywords

FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GEMCITABINE;

AEROSOL; APOPTOSIS; LUNG METASTASIS; MICROENVIRONMENT; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR REGRESSION;

AEROSOLS; ANIMALS; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; DEOXYCYTIDINE; FAS LIGAND PROTEIN; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; OSTEOSARCOMA;

EID: 77955465161     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0812     Document Type: Review

References (43)

1. Young JL Jr, Ries LG., Silverberg E., Horm JW, and Miller RW: Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986;58(2 Suppl): 598-602
2. Hudson M: Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
3. Jaffe N: Osteosarcoma. Pediatr Rev. 1991;12:333-343.
4. Jaffe N: Recent advances in the chemotherapy of metastatic osteogenic sarcoma. 1972. Clin Orthop Relat Res. 1991;270: 4-7.
5. Jaffe N: The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972. Clin Orthop Relat Res. 2005;438:19-21.
6. Jaffe N, Carrasco H, Raymond K, Ayala A, and Eftekhari F: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 2002;95:2202-2210.
7. Marina N. Gebhardtb M. Teotc L. Gorlicket R. Biology and therapeutic advances for pediatric osteosarcoma Oncologist 2004 9 422-441
8. Marina N, Gebhardtb M, Teotc L, and Gorlicket R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-441. 8. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, and Heman JH: Osteosarcoma: the same old drugs or more? J Clin Oncol. 2008;26:3102-3203; author reply 3104-3105.
9. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS, for the Cooperative German-Austrian-Swiss Osteosarcoma Study Group: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
10. Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, Exner GU, Franzius C, Lang S, Maas R, Jürgens H, Gadner H, and Bielack S: Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2006;24:1535-1541.
11. Whelan J, Seddon B, and Perisoglou M: Management of osteosarcoma. Curr Treat Options Oncol. 2006;7:444-455.
12. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG: Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19:1839-1847.
13. Kyle AH, Huxham LA, Chiam ASJ, Sim DH, and Minchinton AI: Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res. 2004;64:6304-6309.
14. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer. 2006l6:583-592.
15. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
16. Symonds H, Krall L, Remington L, Sáenz-Robles M, Jascks T, and Van Dyke T: p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harb Symp Quant Biol. 1994;59:247-257.
17. Nagata S: Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci. 1994;345:281-287.
18. Nagata S, and Golstein P: The Fas death factor. Science. 1995;267:1449-1456.
19. Nagata S: Fas-mediated apoptosis. Adv Exp Med Biol. 1996;406:119-124.
20. Nagata S: Apoptosis by death factor. Cell. 1997;88:355-365.
21. Suda T, Nagata S: Why do defects in the Fas-Fas ligand system cause autoimmunity? J Allergy Clin Immunol. 1997;100(6 Pt 2):S97-S101.
22. Strasser A, Jost PJ, and Nagata S: The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180-192.
23. Ferguson TA, and Griffith TS: A vision of cell death: insights into immune privilege. Immunol Rev. 1997;156:167-184.
24. Ferguson TA, and Griffith TS: A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228-238.
25. Schmidt DS, Eis-Hubinger AM, Schneweis KE: The role of the immune system in establishment of herpes simplex virus latency-studies using CD4 T-cell depleted mice. Arch Virol. 1993;133:179-187.
26. Griffith TS, Yu X, Herndon JM, Green DR, and Ferguson TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
27. Griffith TS, Brunner T, Fletcher SM, Green DR, and Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
28. Griffith TS, and Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997; 18:240-244.
29. Owen-Schaub L, Chan H, Cusack JC, Roth J, and Hill LL: Fas and Fas ligand interactions in malignant disease. Int J Oncol. 2000;17:5-12.
30. Owen-Schaub LB: Fas function and tumor progression: use it and lose it. Cancer Cell. 2002;2:95-96.
31. Jia SF, Worth LL, and Kleinerman ES: A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999;17: 501-506.
32. Worth LL, Lafleur EA, Jia SF, and Kleinerman ES: Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 2002;9:823-827.
33. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, amd Helman L: An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000;18:261-271.
34. Gordon N, Arndt CAS, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, and Kleinerman ES: Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005; 27:611-615.
35. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, and Kleineman ES: Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007;5:991-999.
36. Gordon N, Koshkina NV, Jia S-F, Khanna C, Mendoza A, Worth LL, and Kleinerman ES: Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007;13(15 Pt 1):4503-4510.
37. Galmarini CM, Mackey JR, and Dumontet C: Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875-890.
38. Koshkina NV, Kleinerman ES: Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005;116:458-463.
39. Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo L, Leblond V, Racineux J-L, and Urban T: Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26:657-661.
40. Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, and Anderson PM: Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2009 [E-pub ahead of print].
41. DosReis GA, Borges VM, and Zin WA: The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med. 2004;8:285-1283
42. DosReis GA, and Borges VM: Role of Fas-ligand induced apoptosis in pulmonary inflammation and injury. Curr Drug Targets Inflamm Allergy. 2003;2:161-166.
43. Brambilla E, and Gazdar A: Pathogenesis of lung cancer signaling pathways: roadmap for therapies. Eur Respir J. 2009;33:1485-1497.